Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Marvel Biotechnology identified new adenosine A2A receptor antagonists

Oct. 4, 2021

Primate model of autism spectrum disorder reveals potential therapeutic targets

Oct. 1, 2021

BetterLife Pharma reports neurological receptor binding data for TD-0148A

Sep. 30, 2021

Mindset identifies MSP-4019 and MSP-4020 from Family 4 compounds

Sep. 30, 2021

Model of CDNF gene inactivation points to possible therapies for Parkinson's disease

Sep. 30, 2021

CHIR-99021 acts as mitochondrial function enhancer and shows activity in models of HD

Sep. 30, 2021

Interim data on psilocybin plus NAC in rodent model of mild TBI and PTSD

Sep. 29, 2021

Mitochon announces funding to support development of MP-201 for TBI

Sep. 29, 2021

New humanized Col6a1-mutated knock-in mouse model of collagen VI-related muscular dystrophy

Sep. 29, 2021

Targeting nigral SRY synthesis may be therapeutic for men with Parkinson's disease

Sep. 28, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 19, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Authorities work to quickly sequence Ebola species in latest outbreak
BioWorld
If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...